Last reviewed · How we verify
Placebo; golimumab
Golimumab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling.
Golimumab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling. Used for Rheumatoid arthritis, Psoriatic arthritis, Ankylosing spondylitis.
At a glance
| Generic name | Placebo; golimumab |
|---|---|
| Sponsor | Centocor, Inc. |
| Drug class | TNF-α inhibitor (monoclonal antibody) |
| Target | TNF-α (Tumor Necrosis Factor-alpha) |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Golimumab is a fully human monoclonal antibody that specifically targets TNF-α, a key pro-inflammatory cytokine involved in autoimmune and inflammatory diseases. By blocking TNF-α, it suppresses the inflammatory cascade and reduces immune-mediated tissue damage. This mechanism is effective in conditions where TNF-α plays a central pathogenic role, such as rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease.
Approved indications
- Rheumatoid arthritis
- Psoriatic arthritis
- Ankylosing spondylitis
- Ulcerative colitis
- Crohn's disease
Common side effects
- Infections (including serious infections)
- Injection site reactions
- Upper respiratory tract infections
- Headache
- Tuberculosis reactivation
Key clinical trials
- A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (PHASE2)
- A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis (PHASE2)
- A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (PHASE2)
- A Study of Golimumab in Participants With Active Ankylosing Spondylitis (PHASE3)
- Spondyloarthritis: Inducing Drug-free Remission by Early TNF-alpha Blockade (PHASE3)
- Fecal Microbiota Transplantation in Crohn's Disease as Relay After Anti-TNF Withdrawal (PHASE3)
- A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF(Alpha) Refractory Participants With Active Radiographic Axial Spondyloarthritis (PHASE3)
- A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNFα Naive Participants With Active Radiographic Axial Spondyloarthritis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo; golimumab CI brief — competitive landscape report
- Placebo; golimumab updates RSS · CI watch RSS
- Centocor, Inc. portfolio CI